Table 5.

Multivariable regression for primary and secondary outcomes from SECURE-IBD cohort

Variable (Referent group)a	ICU/Vent/Death Odds Ratio (95% CI) (n = 517)	P	Hospitalization or death Odds Ratio (95% CI) (n =517)	P	Death Odds Ratio (95% CI) (n = 513)	P
Age	1.04 (1.01–1.06)	.002	1.03 (1.01–1.04)	<.001	1.07 (1.03–1.11)	<.001
Male (Femaleb)	1.20 (0.55–2.60)	.65	1.38 (0.89–2.15)	.15	2.78 (0.76–10.14)	.12
Diagnosis
Crohn’s disease (ulcerative colitis/IBD unspecified)	0.76 (0.31–1.85)	.54	0.84 (0.51–1.38)	.49	1.64 (0.42–6.43)	.48
Disease severityc (remission)
Active disease	1.14 (0.49–2.66)	.76	1.96 (1.23–3.11)	.005	0.97 (0.26–3.62)	.96
Systemic corticosteroid (none)	6.87 (2.30–20.51)	<.001	6.46 (2.74–15.23)	<.001	11.62 (2.09–64.74)	.005
TNF antagonist (none)	0.90 (0.37–2.17)	.81	0.60 (0.38–0.96)	.03	0.99 (0.23–4.23)	.99
Current smoker	0.55 (0.06–4.94)	.59	2.38 (0.92–6.16)	.07	1.47 (0.12–17.53)	.76
BMI ≥ 30	2.00 (0.72–5.51)	.18	1.18 (0.61–2.31)	.63	1.58 (0.28–8.80)	.60
Comorbidities (none)
1	1.22 (0.45–3.26)	.70	1.29 (0.76–2.20)	.34	1.64 (0.35–7.67)	.53
≥2	2.87 (1.05–7.85)	.04	4.42 (2.16–9.06)	<.001	2.51 (0.56–11.24)	.23
5-ASA/sulfasalazine (none)	3.14 (1.28–7.71)	.01	1.77 (1.00–3.12)	.05	1.71 (0.46–6.38)	.43

^aWe adjusted each odds ratio for all other variables listed in this table.

^bOther sex excluded from analysis due to low numbers

^cBy physician global assessment (PGA) at time of COVID-19 infection